Your AI-Trained Oncology Knowledge Connection!
Extended adjuvant endocrine therapy via intermittent administration of letrozole did not improve disease-free survival vs continuous use in postmenopausal patients with hormone receptor–positive breast cancer, but represents a valid approach for those who require or prefer a treatment interruption.
The FDA has approved nivolumab for the adjuvant treatment of patients with urothelial carcinoma who are at high risk of recurrence after undergoing radical resection, irrespective of prior neoadjuvant chemotherapy, nodal involvement or PD-L1 status.
Riad Salem MD, discusses previous data with TheraSphere™ Yttrium-90 in metastatic colorectal cancer, the potential role of this modality in the second-line setting, and future research directions.
A collaborative initiative between the American Society of Clinical Oncology and the American Medical Association has the goal of improving well-being and reducing burnout by leveraging a quality improvement framework and model.
The use of transvaginal ultrasonography to measure the need for diagnostic testing of endometrial cancer missed almost 5 times more endometrial cancer cases in Black women compared with those in White women.
Chris Labaki, MD, and Quoc-Dien Trinh, MD, discuss their research on the decline in cancer screenings during the height of the COVID-19 pandemic, the recovery of these tests, and potential existing disparities to be addressed.
It’s imperative to stay diligent of the immune-related adverse events that patients with cancer may experience from checkpoint inhibitors and other immunotherapy agents, especially with regards to treatment continuation and keeping hospitalizations low.
The addition of toripalimab to chemotherapy resulted in a significant improvement in progression-free survival compared with chemotherapy alone when given as first-line treatment in patients with non–small cell lung cancer, meeting the primary end point of the phase 3 CHOICE-01 trial.
The European Commission has granted a conditional marketing authorization for idecabtagene vicleucel for use in adult patients with relapsed/refractory multiple myeloma who have previously received at least 3 therapies, including an immunomodulatory drug, a proteasome inhibitor, and an anti-CD38 antibody and progressed on their last therapy.
The David Liposarcoma Research Initiative will spearhead groundbreaking research into liposarcoma at Dana-Farber and external collaborating partner institutions, with the aim of transforming the treatment of this rare, underfunded, and understudied disease in order to improve care of patients through research.
Nivolumab followed by treatment with tumor-infiltrating lymphocytes was generally safe and found to have clinical benefit in patients with metastatic non–small cell lung cancer.
The discovery of an agent with a unique mechanism of action led investigators to examine sabizabulin, an oral therapy that binds to the colchicine binding site on the microtubule to crosslink α and β tubulin and inhibits microtubule polymerization.
Palbociclib plus ruxolitinib led to normalized blood leukocyte counts, reduced splenomegaly, and significantly improved bone marrow fibrosis in JAK2 V617F and MPLW515L mouse models of myelofibrosis, suggesting that the combination could provide therapeutic benefit to patients with the malignancy.
Overall survival was significantly improved at 18.6 months in patients with non–small cell lung cancer who received targeted therapy compared with those who did not receive targeted therapy at 11.4 months, according to a pooled analysis of patients who received National Comprehensive Cancer Network-guided therapies in accordance with their biomarkers.
Alexey V. Danilov, MD, discusses the safety and efficacy achieved with the novel combination comprised of zandelisib and zanubrutinib in patients with relapsed/refractory B-cell malignancies.
A new publication by Yale Cancer Center highlights recent breakthrough therapies developed to treat non-small cell lung cancer.
The FDA has approved the VENTANA MMR RxDx panel as the first companion diagnostic test to assist in identifying patients with solid tumors that are DNA mismatch repair deficient who may be eligible to receive the anti–PD-1 therapy dostarlimab-gxly, which was recently granted an accelerated approval by the agency.
For patients with mantle cell lymphoma who have progressed after treatment with a BTK inhibitor such as ibrutinib, there is an unmet need for the development of safe and effective targeted therapies to improve otherwise dismal outcomes.
The FDA has granted a fast track designation to STRO-002 as a potential therapeutic option for patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have previously received 1 to 3 lines of systemic therapy.
Circulating tumor DNA, tumor mutational burden, and homologous recombination deficiency are 3 emerging biomarkers for tailoring therapy need further clinical and technical clarity to support robust use in daily practice.
The FDA has granted an accelerated approval to dostarlimab-gxly for the treatment of adult patients with mismatch repair-deficient recurrent or advanced solid tumors, as determined by an FDA-approved test, who have progressed on or following previous treatment and who have no satisfactory alternative options.
Updated efficacy outcomes of the phase 3 MURANO trial demonstrated that fixed-duration venetoclax plus rituximab is an effective treatment approach for patients with relapsed/refractory chronic lymphocytic leukemia and did not compromise response to subsequent therapy or overall survival.
Alexander M. Lesokhin, MD, discusses the promise of elranatamab in the treatment of patients with relapsed/refractory multiple myeloma, the objective of MagnetisMM-3, and other emerging approaches that are generating excitement in the paradigm.
The FDA has granted an orphan drug designation to LP-184 as a potential therapeutic option for patients with pancreatic cancer.
Little Rock—The Myeloma Center at the Winthrop P. Rockefeller Cancer Institute at the University of Arkansas for Medical Sciences is offering a new cutting-edge immunotherapy treatment for myeloma patients.
The European Medicines Agency has validated its Type II Variation Marketing Authorization Applications for nivolumab plus ipilimumab and nivolumab plus fluoropyrimidine- and platinum-containing chemotherapy as frontline options for adult patients with unresectable advanced, recurrent, or metastatic esophageal squamous cell carcinoma.
The FDA has granted an orphan drug designation to the allogeneic CAR T-cell therapy ALLO-715 for the treatment of patients with multiple myeloma.
Average cumulative relative dose was found to be associated with survival over average relative dose intensity in patients with colorectal cancer, highlighting that obese patients receive lower cumulative doses of adjuvant chemotherapy and therefore may be attributed to their poorer survival outcomes.
The FDA has granted an orphan drug designation to CFT7455 for use as a potential therapeutic option in patients with multiple myeloma.
COVID-19 vaccination has been shown to induce high rates of seroconversion in patients with cancer, although those with hematologic malignancies have demonstrated lower immunogenicity and those who previously received immunosuppressive therapies appear to be less responsive.
